
Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Mary Maluccio, MD, MPH, FACS, discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 trial and ongoing patient follow-up.

Dr Mary Maluccio discusses promising results and safety concerns from the ALPHAMEDIX-02 trial on innovative therapy for GEP-NETs.

A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.

Published: October 29th 2025 | Updated:

Published: October 31st 2025 | Updated: